Federal Advocacy

Stay updated on federal initiatives and policies influencing the bio-industry across the country. This category highlights national-level advocacy efforts, initiatives, and developments driving innovation and growth across the industry.

Advocacy Advocacy : Federal Advocacy Advocacy : State Advocacy Association Updates BioConnections® Jobs Event Event : Industry Event Event : MichBio Advocacy Events Event : MichBio Networking Event Event : MichBio Signature Event Event : MichBio Webinar Event : Partner Event Member Feature News News : Industry News News : Member News News : MichBio News/Statement News : Michigan News

Michigan’s own U.S. Representatives John Moolenaar (R-MI) and Debbie Dingell (D-MI) recently introduced the Biotech Investment National...

Read Post

A new proposal under consideration at the National Institutes of Health (NIH) is generating intense discussion across the nation's biomedical...

Read Post

Medical device manufacturers, suppliers, healthcare providers, and investors are closely monitoring a federal trade investigation that could...

Read Post

The Trump administration is advancing one of the most significant restructurings of the federal grantmaking system in decades, proposing changes...

Read Post

Michigan Congressman John Moolenaar, Chair of the House Select Committee on the Chinese Communist Party, has introduced the Securing Innovation...

Read Post

The House Energy & Commerce Committee’s Health Subcommittee has advanced bipartisan legislation aimed at accelerating the FDA’s...

Read Post

For decades, drug development has followed a predictable cadence: run a trial, wait, analyze, submit. Progress has often been defined as much by...

Read Post

Momentum in Congress around Medicare coverage reform for medical devices appears to have slowed following the Administration’s introduction...

Read Post

MichBio joined leaders from across the country in Washington, D.C. for the 2026 Council of StateBioscience Associations (CSBA) Fly-In, bringing...

Read Post

Congress passed long-awaited legislation to reauthorize the SBIR and STTR programs, sending the bill to President Trump on April 1, 2026, for...

Read Post

The White House this past week announced a sweeping new tariff policy targeting imported patented pharmaceutical products, positioning the move as...

Read Post

The Trump Administration’s FY2027 budget proposal underscores a significant shift in federal priorities—pairing a record $1.5 trillion...

Read Post